J 2021

Apolipoprotein E4 Allele in Subjects with COVID-19

HUBACEK, Jaroslav Alois, Lucie DLOUHA, Ladislav DUŠEK, Ondřej MÁJEK, Vera ADAMKOVA et. al.

Basic information

Original name

Apolipoprotein E4 Allele in Subjects with COVID-19

Authors

HUBACEK, Jaroslav Alois (203 Czech Republic, guarantor), Lucie DLOUHA (203 Czech Republic), Ladislav DUŠEK (203 Czech Republic, belonging to the institution), Ondřej MÁJEK (203 Czech Republic, belonging to the institution) and Vera ADAMKOVA (203 Czech Republic)

Edition

GERONTOLOGY, BASEL, KARGER, 2021, 0304-324X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30227 Geriatrics and gerontology

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 5.597

RIV identification code

RIV/00216224:14110/21:00121856

Organization unit

Faculty of Medicine

DOI

UT WoS

000659535900009

Keywords in English

COVID-19; Apolipoprotein E4 Allele

Tags

Tags

International impact, Reviewed
Změněno: 28/6/2021 13:54, Mgr. Tereza Miškechová

Abstract

V originále

We recently read with keen interest a study by Del Ser et al., who suggest that carriers of APOE4 alleles come under increased risk of mild to moderate symptoms of coronavirus disease 2019 (COVID-19) during SARSCoV-2 infection. COVID-19 disease occurs as a consequence of infection with the RNA coronavirus SARSCoV-2. First reported in Wuhan, China, in December 2019, COVID-19 has since spread rapidly and has become a global pandemic. Although highly contagious, the virus is nonetheless associated with relatively low mortality when compared with other coronavirus infections (MERS or SARS).